- Home
- TLX vs KBR Comparison
TLX vs KBR Comparison
Compare TLX & KBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLX
- KBR
- Stock Information
- Founded
- TLX 2015
- KBR 1901
- Country
- TLX Australia
- KBR United States
- Employees
- TLX N/A
- KBR N/A
- Industry
- TLX Biotechnology: Pharmaceutical Preparations
- KBR Military/Government/Technical
- Sector
- TLX Health Care
- KBR Industrials
- Exchange
- TLX Nasdaq
- KBR Nasdaq
- Market Cap
- TLX 5.7B
- KBR 6.3B
- IPO Year
- TLX N/A
- KBR 2006
- Fundamental
- Price
- TLX $15.57
- KBR $46.83
- Analyst Decision
- TLX Strong Buy
- KBR Buy
- Analyst Count
- TLX 3
- KBR 7
- Target Price
- TLX $22.33
- KBR $64.33
- AVG Volume (30 Days)
- TLX 50.1K
- KBR 1.6M
- Earning Date
- TLX 01-01-0001
- KBR 07-31-2025
- Dividend Yield
- TLX N/A
- KBR 1.41%
- EPS Growth
- TLX 798.14
- KBR N/A
- EPS
- TLX 0.09
- KBR 2.98
- Revenue
- TLX $484,687,790.00
- KBR $7,979,000,000.00
- Revenue This Year
- TLX N/A
- KBR $14.27
- Revenue Next Year
- TLX N/A
- KBR $8.57
- P/E Ratio
- TLX $168.47
- KBR $15.72
- Revenue Growth
- TLX 55.85
- KBR 12.84
- 52 Week Low
- TLX $13.61
- KBR $43.89
- 52 Week High
- TLX $30.36
- KBR $72.60
- Technical
- Relative Strength Index (RSI)
- TLX N/A
- KBR 31.89
- Support Level
- TLX N/A
- KBR $46.65
- Resistance Level
- TLX N/A
- KBR $47.86
- Average True Range (ATR)
- TLX 0.00
- KBR 1.08
- MACD
- TLX 0.00
- KBR -0.11
- Stochastic Oscillator
- TLX 0.00
- KBR 4.11
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
About KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: government solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 34,000 people. The firm generated $7.7 billion in revenue in 2024.